Human normal immunoglobulin g (igg) (DrugBank: Human normal immunoglobulin)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
11 | 重症筋無力症 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02774239 (ClinicalTrials.gov) | October 2014 | 20/4/2015 | A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) | A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation | Myasthenia Gravis | Drug: Human normal immunoglobulin G (IgG) | University of Alberta | CSL Behring | Recruiting | 18 Years | 80 Years | All | 30 | Phase 3 | Canada |